BioPharma Resources

Drug Trial Radar · NCT07895355

Phase II Clinical Study of RC148 (ABBV-1480) in Combination With Telisotuzumab Adizutecan (With or Without Chemotherapy) for Unresectable Colorectal Cancer

A Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of RC148 (ABBV-1480) in Combination With Telisotuzumab Adizutecan With or Without Chemotherapy as a First-Line or Second-Line Therapy for Unresectable Colorectal Cancer

Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 412 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

412

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Jul 2028

Study completion Jan 2030

Sponsor

Lead sponsor
RemeGen Co., Ltd.Industry
Sponsor type
Industry
First posted
Oct 26, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RC148 (ABBV-1480) in Combination With Telisotuzumab Adizutecan (With or Without Chemotherapy) for Unresectable Colorectal Cancer

Conditions

  • Patients With Unresectable Colorectal Cancer Requiring First-Line or Second-Line Therapy

Interventions

  • RC148 plus Telisotuzumab adizutecanDrug

    Dose 1/ Dose 1

  • RC148 plus Telisotuzumab adizutecanDrug

    Dose 2/ Dose 1

  • RC148 plus Telisotuzumab adizutecanDrug

    Dose 3/ Dose 2

  • RC148 plus Telisotuzumab adizutecanDrug

    Dose 2/ Dose 2

  • Telisotuzumab adizutecan plus BevacizumabDrug

    Dose 1

  • Telisotuzumab adizutecan plus BevacizumabDrug

    Dose 2

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ORR as assessed by the Investigator per RECIST v1.1Time frame: From randomization date until disease progression, lost to follow-up, withdrawal of informed consent or death, assessed up to approximately 24 months
  2. The incidence and severity of AEs, vital signs, physical examinations, ECGs, and laboratory testTime frame: Screening through 120 days after the last dose of RC148/telisotuzumab adizutecan/bevacizumab or 28 days after the last dose of 5-FU/LV, whichever is late

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen University Cancer Center

    Guangdong, Guangzhou, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.